Arvinas (ARVN) Non-Current Assets (2017 - 2026)
Arvinas' (ARVN) quarterly Non-Current Assets came in at $16.8 million in Q1 2026, down 21.5% year-on-year from $21.4 million in Q1 2025, and down 2.33% quarter-over-quarter from $17.2 million in Q4 2025.
Arvinas (ARVN) Non-Current Assets (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Assets history runs 10 years deep, the most recent figure standing at $16.8 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 21.5% year-over-year to $16.8 million in Q1 2026; TTM through Mar 2026 was $71.8 million, a 16.51% decrease from a year earlier, with the FY2025 full-year figure at $17.2 million, down 28.63% from the prior year.
- Non-Current Assets eased to $16.8 million in Q1 2026 per ARVN's latest filing, from $17.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $31.3 million in Q1 2022 and bottomed at $16.8 million in Q1 2026.
- The 5-year median for Non-Current Assets is $24.1 million (2024), against an average of $23.8 million.
- Across the five-year window, Non-Current Assets jumped 87.81% in 2022 and slumped 30.43% in 2024, its largest moves.
- Year by year, Non-Current Assets stood at $28.6 million in 2022, then fell by 14.69% to $24.4 million in 2023, then dropped by 1.23% to $24.1 million in 2024, then retreated by 28.63% to $17.2 million in 2025, then dropped by 2.33% to $16.8 million in 2026.
- Per Business Quant, the three latest ARVN Non-Current Assets figures stand at $16.8 million (Q1 2026), $17.2 million (Q4 2025), and $18.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 16.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.80 Mn |
| Dec 31, 2025 | 17.20 Mn |
| Sep 30, 2025 | 18.00 Mn |
| Jun 30, 2025 | 19.80 Mn |
| Mar 31, 2025 | 21.40 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 30, 2024 | 17.60 Mn |
| Jun 30, 2024 | 22.90 Mn |
| Mar 31, 2024 | 22.30 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 25.30 Mn |
| Jun 30, 2023 | 26.80 Mn |
| Mar 31, 2023 | 27.60 Mn |
| Dec 31, 2022 | 28.60 Mn |
| Sep 30, 2022 | 30.10 Mn |
| Jun 30, 2022 | 30.60 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Dec 31, 2021 | 29.10 Mn |
| Sep 30, 2021 | 28.71 Mn |
| Jun 30, 2021 | 16.29 Mn |